Background

Anna completed her Bachelor of Biomedical Science (Honours) at the Burnet in 2016, researching crystal methamphetamine use amongst people who inject drugs. In 2019, she completed a Master of Mathematical Sciences (Advanced) at the Australian National University, with a focus on applied mathematics and mathematical modelling of infectious diseases.

Anna now works as a research assistant at Burnet Institute in the Modelling and Biostatistics working group. She works on a variety of mathematical modelling/health economics projects related to injecting drug use and hepatitis C elimination. She intends to continue her career developing mathematical models in public health.

Qualifications

• 2019: Master of Mathematical Sciences (Advanced), The Australian National University, Australia
• 2016: Bachelor of Biomedical Science (Honours), Monash University, Australia
• 2015: Bachelor of Biomedicine, University of Melbourne, Australia

Projects (2)

Current (2)

• 

  COVASIM: Modelling COVID-19

• 

  The elimination of hepatitis C as a global public health threat

Publications (14)

2023 (1)

• Frequent and unpredictable changes in COVID-19 policies and restrictions reduce the accuracy of model forecasts.
  Houdroge F, Palmer A, Delport D, Walsh T, Kelly SL, Hainsworth SW, Abeysuriya R, Stuart RM, Kerr CC, Coplan P, Wilson DP, Scott N
  Sci Rep. 2023 Jan; 13(1):1398

2022 (2)

• Cost optimisation analysis of the expanded programme for immunisation: balancing equity and coverage in Pakistan.
  Houdroge F, Yunus H, Delport D, Stearns E, Palmer A, Naim A, Kashif A, Pyne HH, Scott N, Oelrichs R, Wilson D
  BMJ Glob Health. 2022 Oct; 7(10)
• Assessment of the cost-effectiveness of Australia’s risksharing agreement for direct-acting antiviral treatments for hepatitis C: a modelling study.
  Scott N, Palmer A, Tidhar T, Stoové M, Sacks-Davis R, Doyle JS, Pedrana A, Thompson AJ, Wilson DP, Hellard M
  Lancet Reg Health - West Pac. 2022 Jan; 18:100316

2021 (6)

• A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community-based testing campaign.
  Palmer AY, Chan K, Gold J, Layton C, Elsum I, Hellard M, Stoove M, Doyle JS, Pedrana A, Scott N; EC Partnership
  J Viral Hepat. 2021 Aug; 28(11):1624-1634
• Covasim: An agent-based model of COVID-19 dynamics and interventions.
  Kerr CC, Stuart RM, Mistry D, Abeysuriya RG, Rosenfeld K, Hart GR, Núñez RC, Cohen JA, Selvaraj P, Hagedorn B, George L, Jastrzębski M, Izzo AS, Fowler G, Palmer A, Delport D, Scott N, Kelly SL, Bennette CS, Wagner BG, Chang ST, Oron AP, Wenger EA, Panovska-Griffiths J, Famulare M, Klein DJ
  PLoS Comput Biol. 2021 Jul; 17(7):e1009149
• Prevalence and correlates of simultaneous, multiple substance injection (co-injection) amongst people who inject drugs in Melbourne, Australia.
  Palmer A, Higgs P, Scott N, Agius P, Maher L, Dietze P
  Addiction. 2021 Apr; 116(4):876-888
• A costing analysis of a state-wide, nurse-led hepatitis C treatment model in prison.
  Palmer A, Papaluca T, Stoové M, Winter R, Pedrana A, Hellard M, Wilson D, Thompson A, Scott N; EC Victoria Partnership.
  Int J Drug Policy. 2021 Mar; 94:103203
• Estimating the number of new hepatitis C infections in Australia in 2015, prior to the scale-up of direct-acting antiviral treatment.
  Palmer AY, Wilkinson A, Aitken C, Dietze P, Dore GJ, Maher L, Sacks-Davis R, Stoové M, Wilson D, Hellard M, Scott N
  J Gastroenterol Hepatol. 2021 Mar; 36(8):2270-2274
• Modelling the impact of reducing control measures on the COVID-19 pandemic in a low transmission setting.
  Scott N, Palmer A, Delport D, Abeysuriya R, Stuart R, Kerr CC, Ministry D, Klein D, Sacks-Davis R, Heath K, Hainsworth S, Pedrana A, Stoové M, Wilson D, Hellard ME
  Med J Aust. 2021 Feb; 214(2):79-83

2020 (2)

• Motivations for crystal methamphetamine-opioid co-injection/co-use amongst community-recruited people who inject drugs: a qualitative study.
  Palmer A, Scott N, Dietze P, Higgs P
  Harm Reduct J. 2020 Feb; 17(1):14
• A cost-effectiveness analysis of primary versus hospital-based specialist care for direct acting antiviral hepatitis C treatment.
  Palmer AY, Wade AJ, Draper B, Howell J, Doyle JS, Petrie D, Thompson AJ, Wilson DP, Hellard ME, Scott N
  Int J Drug Policy. 2020 Feb; 76:102633

2019 (1)

• Staying hepatitis C negative: a systematic review and meta-analysis of cure and reinfection in people who inject drugs.
  Latham NH, Doyle JS, Palmer AY, Vanhommerig JW, Agius P, Goutzamanis S, Li Z, Pedrana A, Gottfredsson M, Bouscaillou J, Luhmann N, Mazhnaya A, Altice FL, Saeed S, Klein M, Falade-Nwulia OO, Aspinall E, Hutchinson S, Hellard ME, Sacks-Davis R
  Liver Int. 2019 Dec; 39(12):2244-2260

2018 (1)

• Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study.
  Scott N, Palmer A, Morgan C, Lesi O, Spearman CW, Sonderup M, Hellard M
  Lancet Glob Health. 2018 Jun; 6(6):e659-e667

2017 (1)

• "Just not all ice users do that": investigating perceptions and potential harms of Australia's Ice Destroys Lives campaign in two studies.
  Douglass CH, Early EC, Wright CJC, Palmer A, Higgs P, Quinn B, Dietze PM, Lim MSC
  Harm Reduct J. 2017 Jul; 14(1):45